Side Effects and Efficacy of Immunotherapy

Czech version

Authors: O. Fiala ^1,2; O. Šorejs ^1,2; J. Šustr ¹; J. Fínek ¹
Authors‘ workplace: Onkologická a radioterapeutická klinika LF UK a FN Plzeň ¹; Biomedicínské centrum LF UK v Plzni ²
Published in: Klin Onkol 2020; 33(1): 8-10
Category: Review
doi: https://doi.org/10.14735/amko20208

Overview

Background: Modern immunotherapy based on immune checkpoint inhibitors is an innovative treatment, which is already used in the treatment of a number of malignancies, and many other checkpoint inhibitors have been investigated in clinical trials. Monoclonal antibodies against CTLA-4 (cytotoxic T-lymphocyte antigen-4) and PD-1 (programmed cell death-1) or PD-L1 (programmed cell death-1 ligand) are the most commonly used agents. The side effects of these treatments are similar in nature to those of autoimmune diseases. Recently, increasing evidence has indicated that some adverse effects of immunotherapy are associated with the beneficial effect of this treatment.

Purpose: The aim of this review was to summarize current knowledge of the association between the adverse effects of checkpoint inhibitors and the outcomes of patients treated with this therapy.

Conclusion: The association between the effect of immunotherapy and the occurrence of adverse reactions has been identified in a number of studies. It has been best documented in patients with malignant melanoma, non-small cell lung cancer, and renal cell carcinoma. Many studies published so far are limited by the relatively low number of patients and their retrospective design, leaving many questions still unanswered.

This work was supported by the National Sustainability Program I (NPU I) Nr. LO1503 provided by the Ministry of Education Youth and Sports of the Czech Republic and by the Charles University Research Fund (Progres Q39) and by the European Regional Development Fund-Project „Application of Modern Technologies in Medicine and Industry” (No. CZ.02.1.01/0.0/0.0/17_048/0007280).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 3. 11. 2019

Accepted: 8. 12. 2019

Keywords:

side effects – immunotherapy – checkpoint inhibitors – efficacy

Sources

1. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23 (25): 6043–6053. doi: 10.1200/JCO.2005.06.205.

2. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13 (22): 6681–6688. doi: 10.1158/1078-0432.CCR-07-0187.

3. Teulings HE, Limpens J, Jansen SN et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33 (7): 773–781. doi: 10.1200/JCO.2014.57.4756.

4. Gogas H, Ioannovich J, Dafni U et al. Prognostic significante of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354 (7): 709–718. doi: 10.1056/NEJMoa053007.

5. Boasberg PD, Hoon DS, Piro LD et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126 (12): 2658–2663. doi: 10.1038/sj.jid.5700545.

6. Fujisawa Y, Yoshino K, Otsuka A et al. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients. J Dermatol Sci 2018; 89 (1): 60–66. doi: 10.1016/ j.jdermsci.2017.10.009.

7. Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35 (7): 785–792. doi: 10.1200/JCO.2015.66.1389.

8. Freeman-Keller M, Kim Y, Cronin H et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22 (4): 886–894. doi: 10.1158/1078-0432.CCR-15-1136.

9. Maeda T, Yoshino K, Nagai K et al. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy. Eur J Cancer 2019; 115: 13–16. doi: 10.1016/j.ejca.2019.04.005.

10. Bisschop C, Wind TT, Blank CU et al. Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch expanded access program. J Immunother 2019; 42 (6): 208–214. doi: 10.1097/CJI.0000000000000271.

11. Hasan Ali O, Diem S, Markert E et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016; 5 (11): e1231292. doi: 10.1080/2162402X.2016. 1231292.

12. Haratani K, Hayashi H, Chiba Y et al. Association of immune-related adverse events with nivolumab efficacy in nonesmall-cell lung cancer. JAMA Oncol 2018; 4 (3): 374–378. doi: 10.1001/jamaoncol.2017.2925.

13. Ricciuti B, Genova C, De Giglio A et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 2019; 145 (2): 479–485. doi: 10.1007/s00432-018-2805-3.

14. Grangeon M, Tomasini P, Chaleat S et al. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2019; 20 (3): 201–207. doi: 10.1016/ j.cllc.2018.10.002.

15. Ishihara H, Takagi T, Kondo T at al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 2019; 37 (6): 355.e21–355.e29. doi: 10.1016/j.urolonc.2019.03.003.

16. Verzoni E, Cartenì G, Cortesi E et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 2019; 7 (1): 99. doi: 10.1186/s40425-019-0579-z.